Di Benedetto N, Peralta M, Alvarez E, Schroder MT, Estepo C, Paz S, Fainboim H

Language: English
References: 39
Page: 38-44
PDF size: 100.77 Kb.

ABSTRACT

Introduction. High activity antiretroviral therapy (HAART) has allowed people infected with human immunodeficiency virus (HIV) to live longer. In the course of time, hepatocellular carcinoma (HCC) began to be found in these patients. Investigations have suggested that, as it has been described for other tumors, HIV infection raises the risk of developing HCC. However, convincing evidence is still required. Our aim was to quantify the incidence of HCC in hepatitis C cirrhotic patients with and without human immunodeficiency virus infection in the HAART era. Material and methods. This prospective cohort study was conducted in hepatitis C cirrhotic patients with and without HIV co-infection, between june 1, 1999 and May 21, 2010. Ultrasound screening for HCC was performed every 6 to 12 months to all the patients until January 15, 2011. Incidence rate and cumulative incidence (Kaplan-Meier) were calculated. Results. One hundred and forty eight patients (69 hepatitis C virus mono-infected and 79 HIV/hepatitis C virus co-infected) were followed for a median time of 43 months, with a total follow-up of 555 person-years (324 for co-infected and 231 for mono-infected patients). Twelve patients developed HCC (5 co-infected and 7 mono-infected). The incidence of HCC in co-infected patients and mono-infected patients was 1.54 (95% confidence interval = 0.5 to 3.6) and 3.03 (95% confidence interval = 1.22 to 6.23) cases per 100 person-year respectively (log-rank p = 0.3225). Conclusion. In the HAART era, HIV co-infection is not associated with a higher incidence of HCC in hepatitis C cirrhotic patients.

REFERENCES

1. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, Bonnet F, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study. J Hepatol 2009; 50: 736-45.

2. Rosenthal E, Salmon-Ceron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, Karmochkine M, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Med 2009; 10: 282-9.

3. Fay F, Benetti S, García Camacho G, Bessone F; Schroder T, Fainboim H. Prevalencia de la coinfección HIV/HCV y HIV/HBV en Argentina: Estudio observacional y prospectivo [Abstract]. Acta Gastroenterol Latinoam 2009; 39 (Suppl.): 7.

4. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Couteliier A, Vidaud M, et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. Hepatology 1999; 30: 1054-8.

5. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, Arizcorreta A, et al. Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38: 128-33.

6. Martínez-Sierra C, Arizcorreta A, Díaz F, Roldan R, Martin- Herrera L, Pérez-Guzmán E, Girón-González JA. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2003; 36: 491-8.

7. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang L, El-Serag HB. The effect of HIV co-infection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100: 56-63.

8. Posthouwer D, Makris M, Yee TT, Fischer K, van Veen JJ, Griffioen A, van Erpecum KJ, et al. Progression to endstage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007; 109: 3667-71.

9. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.

10. Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tejpar I, Atkins H, et al. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 1994; 12: 2187-92.

11. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socíe G, Travis LB, Horowitz MM, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.

12. Powles T, Macdonald D, Nelson M, Stebbing J. Hepatocellular cancer in HIV-infected individuals: tomorrow’s problem? Expert Rev Anticancer Ther 2006; 6: 1553-8.

13. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-90.

14. MacDonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008; 14: 1657-63.

15. Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, Trikha A, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47: 527-37.

16. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.

17. Sbolli G, Fornari F, Civardi G, Di Stasi M, Cavanna L, Buscarini E, Buscarini L. Role of ultrasound guided fine needle aspiration biopsy in the diagnosis of hepatocellular carcinoma. Gut 1990; 31: 1303-5.

18. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona- 2000 EASL conference. J Hepatol 2001; 35: 421-30.

19. Bruix J, Sherman M. Management of Hepatocellular Carcinoma. Hepatology 2005; 42: 1208-36.

20. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.

21. Long JL, Engels E, Moore R, Gebo K. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22: 489-96.

22. Colombo M. Hepatitis C virus and hepatocellular carcinoma. Best Pract Res in Clin Gastroenterol 1999; 13: 519-28.

23. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, et al. A Multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.

24. El-Serah HB, Masson AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-5.

25. Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, Rauch A, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22: 2135-41.

26. Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001; 28: 441-9.

27. Bruyand M, Dabis F, Vandenhende MA, Lazaro E, Neau D, Leleux O, Geffard S, et al. HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998-2008. J Hepatol 2011; 55: 1058-62.

28. McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin’s lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006; 24: 5005-9.

29. Garcia-Garcia J, Romero-Gomez M, Giron-Gonzalez J, Rivera- Irigoin R, Torre-Cisneros J, Montero JL, Gonzalez-Serrano M, et al. Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus co-infected patients with decompensated cirrhosis. AIDS Research and Human Retroviruses 2006; 22: 1236-41.

30. Tradati F, Colombo M, Mannucci PM, Rumi MG, De Fazio C, Gamba G, Ciavarella N, et al. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998; 91: 1173-7.

31. Deng LP, Gui XE, Zhang YX, Gao SC, Yang RR. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2009; 15: 996-1003.

32. Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, Trikha A, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47: 527-37.

33. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, Precone D, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18: 2285-93.

34. Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez- Rosado R, Carbo J, Asensi V, Soriano V. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-83.

35. Austin H, Delzell E, Grufferman S, Levine R, Morrison AS, Stolley PD, Cole P. A case-control study of hepatocellular carcinoma and the hepatitis B virus, cigarette smoking, and alcohol consumption. Cancer Res 1986; 46: 962-6.

36. Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, Cramp M, et al. Liver transplantation in adults co-infected with HIV. Transplantation 2001; 72: 1684-8.

37. Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, Heaton N, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-20.

38. Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, Shakil O, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and endstage liver disease. Liver Transpl 2003; 9: 239-47.

39. Fung J, Eghtesad B, Patel-Tom K, DeVera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. Liver Transpl 2004; 10(Suppl.): S39-S53.